Orphan designation is one of the most valuable regulatory assets in Europe — and the rules that govern it are about to change for the first time in a generation.
The current framework is Regulation (EC) No 141/2000. To qualify, a medicine must target a condition affecting no more than 5 in 10,000 people in the EU (or be unlikely to generate sufficient return on investment), and there must be no satisfactory existing method of diagnosis, prevention or treatment — or the product must offer significant benefit over what already exists. The Committee for Orphan Medicinal Products issues the opinion; the Commission decides.
What designation gives you
- Ten years of market exclusivity, extendable by two years with an agreed paediatric investigation plan.
- Protocol assistance — scientific advice tailored to orphan development.
- Fee reductions and access to the centralised procedure.
Significant benefit is where most applications struggle. It is not a one-off test: it must be justified at designation and confirmed at authorisation, against a comparator landscape that may have moved in the intervening years.
Designation is not reimbursement
This is the point most often missed. Designation confers regulatory advantages; it does not oblige any Member State to pay. Access still depends on national health technology assessment and pricing decisions — and the evidence that satisfies the COMP is rarely the evidence that satisfies a payer.
The reform
In December 2025 the Council and Parliament reached political agreement on a comprehensive revision of EU pharmaceutical legislation — the first major overhaul since 2004. For orphan medicines, the headline confirmed by Parliament is that products addressing a disease with no currently available treatment — so-called “breakthrough” orphan medicinal products — would benefit from up to eleven years of market exclusivity, alongside early regulatory guidance for promising orphan medicines well before an application is filed.
Wider changes include eight years of regulatory data protection plus one year of market protection, extendable but capped at eleven years combined; a widened Bolar exemption covering HTA, pricing and reimbursement approvals and procurement tenders; and marketing authorisations valid for unlimited duration by default.
A word of caution: this is an early second reading agreement. The final legal texts are not yet published, and various figures circulating in commentary are not yet confirmed by an official source. Plan for the direction of travel, not the details.
How PQRA helps
PQRA supports orphan designation applications, significant benefit argumentation, protocol assistance and the route from designation through to Greek reimbursement.
No responses yet